Mestinon 60mg tablets

Quốc gia: Vương quốc Anh

Ngôn ngữ: Tiếng Anh

Nguồn: MHRA (Medicines & Healthcare Products Regulatory Agency)

Thành phần hoạt chất:

Pyridostigmine bromide

Sẵn có từ:

CST Pharma Ltd

Mã ATC:

N07AA02

INN (Tên quốc tế):

Pyridostigmine bromide

Liều dùng:

60mg

Dạng dược phẩm:

Oral tablet

Tuyến hành chính:

Oral

Lớp học:

No Controlled Drug Status

Loại thuốc theo toa:

Valid as a prescribable product

Tóm tắt sản phẩm:

BNF: 10020100; GTIN: 5055946801575

Tờ rơi thông tin

•
Suffer from a condition called
vagotonia (this is a condition
where overactivity of the
vagus nerve causes symptoms
such as slow heart rate, low
blood pressure, constipation,
sweating and painful muscle
spasms).
•
Have an overactive thyroid
gland
•
Have had an operation to remove your thymus
gland.
There is no evidence to suggest that Mestinon has any
special effects on elderly patients.
TAKING OTHER MEDICINES
Please tell your doctor or pharmacist if you are taking
or have recently taken any other medicines, including
medicines obtained without a prescription.
THIS IS EXTREMELY IMPORTANT, as using more than
one medicine at the same time can strengthen or
weaken the effect of the medicines. In particular, tell
your
doctor if you are taking any of the following
medicines:
•
Medicines known as steroids or other
immunosuppressant medicines.
•
Medicines known as antimuscarinics
(e.g. atropine, hyoscine).
•
Medicines containing methylcellulose
• Antibiotics
•
Medicines to treat an irregular heart beat
•
Other medicines that interfere with transmission
between nerves and muscles
IF YOU ARE GOING TO HAVE SURGERY
Tell your doctor that you are taking Mestinon.
Mestinon can stop the effect of some medicines used
to relax muscles during surgery (e.g. pancuronium,
vencuronium).
Mestinon can also prolong the effect of other muscle
relaxants (e.g. suxamethonium).
PREGNANCY AND BREAST-FEEDING
Tell your doctor before you start treatment if you:
•
Are pregnant, if you think you are pregnant,
or if you intend to become pregnant.
•
Are breast-feeding, as Mestinon passes into breast
milk in small amounts.
Your doctor will then decide if you can take this
medicine.
DRIVING AND USING MACHINES
Mestinon may reduce the sharpness of your eyesight
and therefore your ability to drive or use machines.
Do not drive or operate machines if this medicine
affects your ability to see clearly.
IMPORTANT INFORMATION ABOUT SOME OF THE
INGREDIENTS OF MESTINON TABLETS
M
estinon Tablets contain lactose. Therefore, if you
have been

Đặc tính sản phẩm

_SUMMARY OF PRODUCT CHARACTERISTICS _
1
NAME OF THE MEDICINAL PRODUCT
Mestinon 60 mg Tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 60 mg pyridostigmine bromide.
For the full list of excipients, see section 6.1
3
PHARMACEUTICAL FORM
Tablet for oral administration.
White to off-white, round, biplanar, bevel-edged tablets imprinted
with “ V ”
M60
across one face and with two break marks forming a cross on the other.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Myasthenia gravis, paralytic ileus and post-operative urinary
retention.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Myasthenia gravis
Adults
Doses of 30 to 120mg are given at intervals throughout the day when
maximum
strength is needed (for example, on rising and before mealtimes). The
usual duration
of action of a dose is 3 to 4 hours in the daytime but a longer effect
(6 hours) is often
obtained with a dose taken on retiring for bed.
The total daily dose is usually in the range of 5 – 20 tablets but
doses higher than
these may be needed by some patients.
Paediatric population
Children under 6 years old should receive an initial dose of half a
tablet (30mg) of
Mestinon; children 6 – 12 years old should receive one tablet
(60mg). Dosage should
be increased gradually, in increments of 15 – 30mg daily, until
maximum
improvement is obtained. Total daily requirements are usually in the
range to 30 –
360mg.
Other Indications (paralytic ileus, post-operative urinary retention)
Adults
The usual dose is 1 to 4 tablets (60 – 240mg) per day.
Paediatric population
The usual dose is 15 – 60mg per day.
The frequency of these doses may be varied according to the needs of
the patient.
Special populations
Elderly
There are no specific dosage recommendations for Mestinon in elderly
patients.
Renal impairment
Mestinon is mainly excreted unchanged by the kidney, therefore lower
doses may be
required in patients with renal disease and treatment should be based
on titration of
drug dosage to effect.
Hepatic impairment
There a